| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| IgGenix Grabs $10M to Advance Antibody Treatments for Allergies | Sarah de Crescenzo | 08/05/20 | San Francisco |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA | Frank Vinluan | 09/13/19 | San Francisco |
| FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb | Frank Vinluan | 09/11/19 | San Francisco |
| DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead | Frank Vinluan | 02/13/19 | National |
| Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More | Alex Lash | 01/25/19 | National |
| Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More | Frank Vinluan | 11/16/18 | National |
| Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More | Frank Vinluan | 02/23/18 | National |
| Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned | Frank Vinluan | 02/20/18 | San Francisco |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 2) | Alex Lash | 12/06/17 | National |
| RA Capital Seeds Peanut Allergy Prevention Startup With $1.7M | David Holley | 06/01/16 | Boston |
| Aimmune Prices Upsized $160M IPO, Climbs Higher in Debut | David Holley | 08/06/15 | San Francisco |
